Capital Increase in Genmab as a Result of Employee Warrant Exercise
22 September 2021 - 4:22AM
Company Announcement
COPENHAGEN, Denmark;
September 21,
2021
– Genmab A/S
(Nasdaq:
GMAB) will increase its
share capital by 3,969 shares as
a consequence of the exercise of
employee warrants.
The increase is effected without any preemption rights for the
existing shareholders of the company or others. The shares are
subscribed in cash at the following price per share of nominally
DKK 1:
1,800 shares at DKK 337.40,1,875 shares at DKK 939.50,144 shares
at DKK 1,145.00, and150 shares at DKK 1,210.00.
Proceeds to the company are approximately DKK 2.7 million. The
increase corresponds to approximately 0.01% of the company's share
capital.
The new shares are ordinary shares without any special rights
and are freely transferable negotiable instruments. The new shares
give rights to dividends and other rights in relation to the
company as of subscription. The new shares will be listed on Nasdaq
Copenhagen after registration with the Danish Business Authority.
The capital increase is expected to be finalized shortly.
Pursuant to section 32 of the Danish Capital Markets Act No.
1767 of November 27, 2020, it is hereby announced, that the total
nominal value of Genmab A/S' share capital after the capital
increase is DKK 65,685,053 which is made up of 65,685,053 shares of
a nominal value of DKK 1 each, corresponding to 65,685,053
votes.
About Genmab Genmab is an international
biotechnology company with a core purpose to improve the lives of
people with cancer. For more than 20 years, Genmab’s vision to
transform cancer treatment has driven its passionate, innovative
and collaborative teams to invent next-generation antibody
technology platforms and leverage translational research and data
sciences, fueling multiple differentiated cancer treatments that
make an impact on people’s lives. To develop and deliver novel
therapies to patients, Genmab has formed 20+ strategic partnerships
with biotechnology and pharmaceutical companies. Genmab’s
proprietary pipeline includes bispecific T-cell engagers,
next-generation immune checkpoint modulators, effector function
enhanced antibodies and antibody-drug conjugates.
Genmab is headquartered in Copenhagen, Denmark with
locations in Utrecht, the Netherlands, Princeton, New Jersey, U.S.
and Tokyo, Japan. For more information, please visit Genmab.com and
follow us on Twitter.com/Genmab.
Contact: Marisol
Peron, Senior Vice President, Global Investor Relations &
CommunicationsT: +1 609 524 0065; E: mmp@genmab.com
For Investor Relations: Andrew Carlsen, Vice
President, Head of Investor RelationsT: +45 3377 9558; E:
acn@genmab.com This Company Announcement contains forward looking
statements. The words “believe”, “expect”, “anticipate”, “intend”
and “plan” and similar expressions identify forward looking
statements. Actual results or performance may differ materially
from any future results or performance expressed or implied by such
statements. The important factors that could cause our actual
results or performance to differ materially include, among others,
risks associated with pre-clinical and clinical development of
products, uncertainties related to the outcome and conduct of
clinical trials including unforeseen safety issues, uncertainties
related to product manufacturing, the lack of market acceptance of
our products, our inability to manage growth, the competitive
environment in relation to our business area and markets, our
inability to attract and retain suitably qualified personnel, the
unenforceability or lack of protection of our patents and
proprietary rights, our relationships with affiliated entities,
changes and developments in technology which may render our
products or technologies obsolete, and other factors. For a further
discussion of these risks, please refer to the risk management
sections in Genmab’s most recent financial reports, which are
available on www.genmab.com and the risk factors included in
Genmab’s most recent Annual Report on Form 20-F and other filings
with the U.S. Securities and Exchange Commission (SEC), which are
available at www.sec.gov. Genmab does not undertake any obligation
to update or revise forward looking statements in this Company
Announcement nor to confirm such statements to reflect subsequent
events or circumstances after the date made or in relation to
actual results, unless required by law. Genmab A/S and/or its
subsidiaries own the following trademarks: Genmab®; the Y-shaped
Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®;
HuMax®; DuoBody®; DuoBody in combination with the DuoBody logo®;
HexaBody®; HexaBody in combination with the HexaBody logo®;
DuoHexaBody® and HexElect®.
Company Announcement no. 63CVR no. 2102 3884LEI Code
529900MTJPDPE4MHJ122
Genmab A/SKalvebod Brygge 431560 Copenhagen VDenmark
- 210921_CA63_warrant exercise
Genesis Healthcare (NYSE:GEN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Genesis Healthcare (NYSE:GEN)
Historical Stock Chart
From Sep 2023 to Sep 2024